Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback